Comparison of Preoperative Alpha-blockade for Resection of Paraganglioma and Pheochromocytoma.
adrenalectomy
alpha-blockade
paraganglioma
pheochromocytoma
Journal
Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
ISSN: 1530-891X
Titre abrégé: Endocr Pract
Pays: United States
ID NLM: 9607439
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
11
04
2022
revised:
28
06
2022
accepted:
30
06
2022
pubmed:
10
7
2022
medline:
14
9
2022
entrez:
9
7
2022
Statut:
ppublish
Résumé
Phenoxybenzamine (nonselective, noncompetitive alpha-blocker) is the preferred drug for preoperative treatment of pheochromocytoma, but doxazosin (selective, competitive alpha-blocker) may be equally effective. We compared the efficacy of doxazosin vs phenoxybenzamine. We conducted a prospective study of patients undergoing pheochromocytoma or paraganglioma resection by randomizing pretreatment with phenoxybenzamine or doxazosin at a single tertiary referral center. The high cost of phenoxybenzamine led to high crossover to doxazosin. Randomization was halted, and a consecutive historical cohort of phenoxybenzamine patients was included for a case-control study design. The efficacy of alpha-blockade was assessed with preinduction infusion of incremental doses of phenylephrine. The primary outcomes were mortality, cardiovascular complications, and intensive care unit admission. The secondary outcomes were hemodynamic instability index (proportion of operation outside of hemodynamic goals), adequacy of blockade by the phenylephrine titration test, and drug costs. Twenty-four patients were prospectively enrolled (doxazosin, n = 20; phenoxybenzamine, n = 4), and 15 historical patients treated with phenoxybenzamine were added (total phenoxybenzamine, n = 19). No major cardiovascular complications occurred in either group. The phenylephrine dose-response curves showed less blood pressure rise in the phenoxybenzamine than in the doxazosin group (linear regression coefficient = 0.008 vs 0.018, P = .01), suggesting better alpha-blockade in the phenoxybenzamine group. The median hemodynamic instability index was 14% vs 13% in the phenoxybenzamine and doxazosin groups, respectively (P = .56). The median highest daily cost of phenoxybenzamine was $442.20 compared to $5.06 for doxazosin. Phenoxybenzamine may blunt intraoperative hypertension better than doxazosin, but this difference did not translate to fewer cardiovascular complications and is offset by a considerably increased cost.
Identifiants
pubmed: 35809774
pii: S1530-891X(22)00548-1
doi: 10.1016/j.eprac.2022.06.013
pii:
doi:
Substances chimiques
Adrenergic alpha-Antagonists
0
Phenoxybenzamine
0TTZ664R7Z
Phenylephrine
1WS297W6MV
Doxazosin
NW1291F1W8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
889-896Informations de copyright
Copyright © 2022 AACE. Published by Elsevier Inc. All rights reserved.